Literature DB >> 31378131

miR-142-3p as a novel biomarker for predicting poor prognosis in renal cell carcinoma patients after surgery.

Xiqi Peng1,2, Xiang Pan3, Kaihao Liu1, Chunduo Zhang1, Liwen Zhao1, Hang Li1, Xin Guan1, Weijie Xu1, Jinling Xu1, Fangting Zhang1, Yongqing Lai1.   

Abstract

BACKGROUND: miR-142-3p has proved to be involved in tumorigenesis and the development of renal cell carcinoma. The present study aimed to explore the prognostic value of miR-142-3p.
METHODS: Total RNA was extracted from renal cell carcinoma specimens and the expression level of miR-142-3p was measured. Pearson Chi-square test, Kaplan-Meier analysis, as well as univariate and multivariate regression analysis were performed to determine the correlation between miR-142-3p and the prognosis of renal cell carcinoma patients. Receiver operating characteristic curves were constructed to evaluate the predictive efficiency of miR-142-3p for the prognosis of renal cell carcinoma patients. Data from The Cancer Genome Atlas (TCGA) were utilized to validate our findings.
RESULTS: Our results demonstrated that upregulation of miR-142-3p was correlated with shorter overall survival (P=0.002) and was, in the meantime, an independent prognostic factor for renal cell carcinoma patients (P=0.002). The receiver operating characteristic curve combining miR-142-3p expression with tumor stage showed an area under the curve of 0.633 (95% confidence interval 0.563, 0.702). The result of TCGA data was consistent with our findings.
CONCLUSIONS: Our results suggest miR-142-3p expression is correlated with poor prognosis of renal cell carcinoma patients and may serve as a prognostic biomarker in the future.

Entities:  

Keywords:  miR-142-3p; microRNA; prognostic biomarker; renal cell carcinoma (RCC)

Mesh:

Substances:

Year:  2019        PMID: 31378131     DOI: 10.1177/1724600819866456

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  5 in total

1.  Renal cancer stem cell-derived sEVs impair renal function by inducing renal cell ERS and apoptosis in mice.

Authors:  Ruoyu Wu; Zhiguo Chen; Junjie Ma; Wenjie Huang; Ke Wu; Yang Chen; Junhua Zheng
Journal:  Transl Androl Urol       Date:  2022-05

2.  Prognostic value of miR-142 in solid tumors: a meta-analysis.

Authors:  Rongqiang Liu; Shiyang Zheng; Kang Yu; Yajie Yu; Chenyu Yu; Wenqing Shi; Qianmin Ge; Zhiwei Ye; Yi Shao
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

3.  The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma.

Authors:  Keying Zhang; Chao Xu; Shaojie Liu; Yao Jiang; Xiaolong Zhao; Shanjin Ma; Yu Li; Fa Yang; Yan Wang; Ping Meng; Changhong Shi; Donghui Han; Weihong Wen; Weijun Qin
Journal:  Front Oncol       Date:  2021-03-12       Impact factor: 6.244

4.  Aberrant Expression of miR-592 Is Associated with Prognosis and Progression of Renal Cell Carcinoma.

Authors:  Xianbao Lv; Jingang Shen; Zhen Guo; Lingwei Kong; Guangchun Zhou; Hao Ning
Journal:  Onco Targets Ther       Date:  2019-12-18       Impact factor: 4.147

5.  Comprehensive Analysis of a ceRNA Network Identifies lncR-C3orf35 Associated with Poor Prognosis in Osteosarcoma.

Authors:  Yi Shi; Jianhua Ren; Ze Zhuang; Wenhui Zhang; Zhe Wang; Yuangao Liu; Jinze Li; Tangzhao Liang; Ronghan He; Kun Wang
Journal:  Biomed Res Int       Date:  2020-09-21       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.